Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
We investigated the mechanisms by which inhibitors of prostaglandin G/H synthase-2 (PGHS-2; known colloquially as COX-2) increase the incidence of myocardial infarction and stroke. These inhibitors are believed to exert both their beneficial and their adverse effects by suppression of PGHS-2-derived prostacyclin (PGI(2)) and PGE(2). Therefore, the challenge remains to identify a mechanism whereby PGI(2) and PGE(2) expression can be suppressed while avoiding adverse cardiovascular events. Here, selective inhibition, knockout, or mutation of PGHS-2, or deletion of the receptor for PGHS-2-derived PGI(2), was shown to accelerate thrombogenesis and elevate blood pressure in mice. These responses were attenuated by COX-1 knock down, which mimics the beneficial effects of low-dose aspirin. PGE(2) biosynthesis is catalyzed by the coordinate actions of COX enzymes and microsomal PGE synthase-1 (mPGES-1). We show that deletion of mPGES-1 depressed PGE(2) expression, augmented PGI(2) expression, and had no effect on thromboxane biosynthesis in vivo. Most importantly, mPGES-1 deletion affected neither thrombogenesis nor blood pressure. These results suggest that inhibitors of mPGES-1 may retain their antiinflammatory efficacy by depressing PGE(2), while avoiding the adverse cardiovascular consequences associated with PGHS-2-mediated PGI(2) suppression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cyclooxygenases: Structural, cellular, and molecular biology
Smith, W. L., DeWitt, D. L., & Garavito, R. M. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.145 · Cited by 2,925
Penning, T. D., Talley, J. J., Bertenshaw, S. R., Carter, J. S., Collins, P. W., Docter, S., Graneto, M. J., Lee, L. F., Malecha, J. W., Miyashiro, J. M., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960803q · Cited by 1,965
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., & FitzGerald, G. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003199 · Cited by 1,394
McAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,305
An Fgf8 mutant allelic series generated by Cre- and Flp-mediated recombination
Meyers, E. N., Lewandoski, M., & Martin, G. R. (1998) · Nature Genetics · doi:10.1038/ng0298-136 · Cited by 1,031
Grosser, T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci27291 · Cited by 1,027
Coxibs and Cardiovascular Disease
FitzGerald, G. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048288 · Cited by 899
Role of Prostacyclin in the Cardiovascular Response to Thromboxane A 2
Cheng, Y., Austin, S. C., Rocca, B., Koller, B. H., Coffman, T. M., Grosser, T., Lawson, J. A., & FitzGerald, G. A. (2002) · Science · doi:10.1126/science.1068711 · Cited by 789
Self-citationAltered pain perception and inflammatory response in mice lacking prostacyclin receptor
Murata, T., Ushikubi, F., Matsuoka, T., Hirata, M., Yamasaki, A., Sugimoto, Y., Ichikawa, A., Aze, Y., Tanaka, T., Yoshida, N., et al. (1997) · Nature · doi:10.1038/41780 · Cited by 773
Catella-Lawson, F., McAdam, B., Morrison, B. W., Kapoor, S., Kujubu, D., Antes, L., Lasseter, K. C., Quan, H., Gertz, B. J., & Fitzgerald, G. A. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38195-9 · Cited by 597
Cited by
Platelet Activation and Atherothrombosis
Davì, G., & Patrono, C. (2007) · New England Journal of Medicine · doi:10.1056/nejmra071014 · Cited by 2,135
Rao, P., & Knaus, E. E. (2008) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3t886 · Cited by 773
Prostaglandins, NSAIDs, and Gastric Mucosal Protection: Why Doesn't the Stomach Digest Itself?
Wallace, J. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00004.2008 · Cited by 716
Prostanoids in health and disease
Smyth, E. M., Grosser, T., Wang, M., Yu, Y., & FitzGerald, G. A. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800094-jlr200 · Cited by 543
Membrane Prostaglandin E Synthase-1: A Novel Therapeutic Target
Samuelsson, B., Morgenstern, R., & Jakobsson, P.-J. (2007) · Pharmacological Reviews · doi:10.1124/pr.59.3.1 · Cited by 538
Platelets at work in primary hemostasis
Broos, K., Feys, H. B., De Meyer, S. F., Vanhoorelbeke, K., & Deckmyn, H. (2011) · Blood Reviews · doi:10.1016/j.blre.2011.03.002 · Cited by 502
Molecular Biology of Atherosclerosis
Hopkins, P. N. (2013) · Physiological Reviews · doi:10.1152/physrev.00004.2012 · Cited by 459
Aspirin Dose for the Prevention of Cardiovascular Disease: A Systematic Review
Campbell, C. L., Smyth, S., Montalescot, G., & Steinhubl, S. R. (2007) · JAMA · doi:10.1001/jama.297.18.2018 · Cited by 444
Clinical Pharmacology of Non-Steroidal Anti-Inflammatory Drugs: A Review
Bacchi, S., Palumbo, P., Sponta, A., & Coppolino, M. F. (2012) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/187152312803476255 · Cited by 433
Interplay between platelets and coagulation
Sang, Y., Roest, M., de Laat, B., de Groot, P. G., & Huskens, D. (2021) · Blood Reviews · doi:10.1016/j.blre.2020.100733 · Cited by 405
Wada, M., DeLong, C. J., Hong, Y. H., Rieke, C. J., Song, I., Sidhu, R. S., Yuan, C., Warnock, M., Schmaier, A. H., Yokoyama, C., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703169200 · Cited by 400
Endothelium‐mediated control of vascular tone: COX‐1 and COX‐2 products
Félétou, M., Huang, Y., & Vanhoutte, P. M. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01276.x · Cited by 372
COX-2 Inhibitors and Cardiovascular Risk
Funk, C. D., & FitzGerald, G. A. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318157f72d · Cited by 330
Timing of expression of the core clock gene Bmal1 influences its effects on aging and survival
Yang, G., Chen, L., Grant, G. R., Paschos, G., Song, W.-L., Musiek, E. S., Lee, V., McLoughlin, S. C., Grosser, T., Cotsarelis, G., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad3305 · Cited by 317
NSAIDs and Cancer Prevention: Targets Downstream of COX-2
Cha, Y. I., & DuBois, R. N. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131253 · Cited by 308
Nonsteroidal Anti-Inflammatory Drugs and the Kidney
Hörl, W. H. (2010) · Pharmaceuticals · doi:10.3390/ph3072291 · Cited by 298
“In contrast, deletion or inhibition of COX-2 reduces renal medullary blood flow and sodium excretion, increases the vasoconstrictive response to angiotensin II [134] and elevates blood pressure [135].”
BackgroundInflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer
Howe, L. R. (2007) · Breast Cancer Research · doi:10.1186/bcr1678 · Cited by 293
Pathophysiological role of prostaglandin E synthases in liver diseases
Xu, D., Cai, J., Wan, Z.-K., Gao, H., & Sun, Y. (2021) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2021.106552 · Cited by 10
Metadata
- Authors
- Cheng, Y.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-05-01
- Volume
- 116
- Issue
- 5
- Pages
- 1391-1399
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2006306072
- Cited by
- 339
- References
- 53
- FWCI
- 17.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.